Jason Hoffman, PharmD, RPh

Carfilzomib significantly prolonged overall survival compared with bortezomib in patients with relapsed or refractory multiple myeloma.

Oncology nurse navigators improved physician engagement in multidisciplinary discussions prior to the initiation of treatment for patients with head and neck cancer.

A clinical pathways navigation program for patients with non-small cell lung cancer significantly reduced cost of care while preserving clinical outcomes.

The addition of pravastatin to first-line chemotherapy did not improve overall survival or progression-free survival in patients with small-cell lung cancer.

Internet-based cognitive behavioral therapy has positive effects on sexual functioning in breast cancer survivors experiencing sexual dysfunction.

Patients with hormone receptor-positive, HER2-negative, axillary lymph node-negative breast cancer who have a recurrence score of 11 to 25 may not benefit from chemotherapy.

Early palliative care significantly reduced the use of the intensive care unit in patients with advanced cancer at the end of life.

HER-2 enriched subtype predicts for HER2 blockade benefit with lapatinib and trastuzumab

Risk of chemotherapy-induced hair loss common to breast cancer therapy may be reduced with the use of scalp-cooling device.

Ceritinib has been granted Priority Review as a first-line treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.